Loading
NASDAQHealthcareBiotechnology
Latest quote
$345.55
−$2.54 · -0.73%
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Latest quote
$345.55
−$2.54 · -0.73%
After-hours
$361
+$15.45 · +4.47%
Sep 10, 7:09 PM ET
Regular session · ET · Market data may be delayed.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Day range
Current $345.55
52-week range
Current $345.55
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
80
Undervalued
Sentiment
50
Mixed
Risk
22
Moderate Risk
Momentum
78
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Day range
Current $345.55
52-week range
Current $345.55
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 389.13M USD | 290.52M USD | 50.7M USD | — | — |
| Cost of goods sold | 28.77M USD | 20.06M USD | 3.09M USD | — | — |
| Gross profit | 360.36M USD | 270.45M USD | 47.61M USD | — | — |
| Research and development | 58.05M USD | 53.57M USD | 46.43M USD | 42.46M USD | 27.88M USD |
| Selling, general, and administrative | 146.74M USD | 113.69M USD | 98.4M USD | 77.74M USD | 40.39M USD |
| Operating expenses | 199.06M USD | 204.76M USD | 157.33M USD | 145.2M USD | 68.28M USD |
| Interest income | 28.18M USD | 29.66M USD | 22.62M USD | 5.22M USD | 197K USD |
| Interest expense | — | — | — | — | 1.49M USD |
| Depreciation and amortization | 6.55M USD | 6.71M USD | 5.91M USD | 3.39M USD | 1.85M USD |
| Operating income | 161.3M USD | 65.7M USD | −109.73M USD | −145.2M USD | −68.28M USD |
| Net income | 204.83M USD | 89.16M USD | 10.93M USD | −139.98M USD | −69.57M USD |
Company facts updated Sep 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Mid-Cap ETFIJH304.73M0.24%126.02B USD0.05%$73.86-0.94%
Vanguard Morningstar Total Stock Market ETFVTI304.43M0.01%2.3T USD0.03%$373.24-0.62%
iShares Russell 2000 ETFIWM230.96M0.29%80.51B USD0.19%$287.7-1.01%
Vanguard Morningstar Small-Cap ETFVB219.54M0.12%183.4B USD0.03%$291.18-0.99%
Vanguard Morningstar Small-Cap Growth ETFVBK127.1M0.28%43.8B USD0.05%$337.98-1.41%
State Street SPDR S&P Biotech ETFXBI120.11M1.06%11.33B USD0.35%$156.82-1.61%
Vanguard Extended Market ETFVXF103.01M0.11%93.7B USD0.05%$236.16-1.05%
iShares Russell 2000 Growth ETFIWO85.6M0.59%14.7B USD0.24%$365.67-1.42%iShares Core S&P Mid-Cap ETFIJHVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
